Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.63 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | GHSR | Q92847 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.53 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840654 | 0.89 | PPIA (0.63) | ALDH1A1FFAR1FFAR4LMNAMAPT | |
| SCHEMBL15840815 | 0.87 | ALDH1A1 (0.76) | ALDH1A1LMNAMAPTGHSRKMT2A | |
| Water SCHEMBL27650777 | 0.87 | FFAR1 (0.72) | ALDH1A1FFAR1FFAR4LMNAGHSR | |
| SCHEMBL28219031 | 0.86 | FFAR1 (0.74) | ALDH1A1FFAR1FFAR4LMNAMAPT | |
| SCHEMBL6684707 | 0.85 | ALDH1A1 (0.72) | ALDH1A1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL3396831 | 0.84 | ALDH1A1 (0.85) | ALDH1A1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL11891712 | 0.83 | FFAR1 (0.66) | ALDH1A1FFAR1FFAR4GHSRKMT2A | |
| SCHEMBL31681351 | 0.81 | FFAR4 (0.81) | FFAR1FFAR4LMNAMAPTGHSR | |
| SCHEMBL7173225 | 0.80 | FFAR1 (0.74) | FFAR1FFAR4LMNAGHSRSMN1; SMN2 | |
| SCHEMBL11027242 | 0.80 | FFAR1 (0.66) | ALDH1A1FFAR1FFAR4LMNAGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | ALDH1A1 4348/4885FFAR1 2431/4885FFAR4 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.